Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML (clinicaltrials.gov) - Aug 26, 2025 - P1/2 | N=24 | Terminated | Sponsor: Sutro Biopharma, Inc. | Trial completion date: Mar 2029 ➔ Jun 2025 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2028 ➔ Jun 2025; Terminated Early
Trial completion date • Trial primary completion date • Trial termination • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
|